Member Info for Rudey

Peter, so many trades are not disclosed by the market makers until after trading hours, that trying to gauge whether the price is going to go up or down is nigh on impossible. If you are trading, ie buying and selling to make a profit, not only are you likely to lose money but small fluctuations can be misleading.
In my opinion this is a share to invest in but not attempt to trade. You may have a meltdown like some investors do. Best to invest and not watch the share price too much.

moniman, I find deepjoy's posts far more interesting than yours. Afterall, as you previously posted, you will vary the opinion you give on here according to whether you are buying or selling. That makes your posts hardly worth reading.

Of course knowing that CF is seeking a merger or buyout by a blank cheque company may persuade big pharma companies to step in before it's too late to acquire these important assets.

From an ORPH investors perspective it's the sale value of these vaccines that's exciting.

The 'Holy Grail' mosquito vaccine coupled with one of the only 2 phase 3 ready universal flu vaccines worldwide is manner from heaven for CF as far as marketing is concerned. But unless the Imutex bundle is merged into a NASDAQ special purpose acquisition company (and not sold), shareholders will no longer have a direct financial interest in these vaccines as they progress beyond the stages they are currently at.

I have no doubt that however CF deals with this bundle it will be the best possible outcome for shareholders. The 9th of July presentation could end up being transformational and provide a very nice dividend - maybe by the end of the summer.

They'll both be sold before the next stage.

I suppose It also means you could have 16, 32, 40, 48 etc. Ivy, participating in a study of varying lengths.

Ivy, he has said they can run 3 studies simultaneously, as the clinic is in 3 sections of 8 beds.

deepjoy & Ivy, it's an opportunity to present the Imutex bundle to big finance. Open Orphan own 49% of Imutex, 62% of PrEPBiopharm and 100% of our own immune modulator, CF has a background in making deals so he's the right person to cut a deal. It's not to promote Open Orphan, it's to vend the bundle into a cash SPAC blank cheque company in a very short time frame in my opinion. Somehow it's relevance is being lost here.

CF said ALL Link/Acacia's shares are being or have been sold on the open market.

deepjoy, at that presentation he must be looking to vend the Imutex bundle into a blank-cheque company for cash or merger. Open Orphan doesn't need further funding as things stand.

deepjoy, you posted:
'if he is speaking to an investor seminar next month aimed at big money investment why would he need to if they were already queuing at the door given the present SP and what is the capital and therefore dilution set to achieve?'
You clearly either don't understand the significance or you are trying to misrepresent this RNS. There is a huge difference between raising £12m and having a blank cheque.

Indiscipline, it's not an ordinary presentation - he's clearly after big finance. It must be the Imutex bundle imo.

Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020

'Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors.'

Must be to do with the cash SPAC the Imutex bundle could be vended into. Cathal Friel doesn't hang about.

I wonder if this is to do directly with the Imutex bundle.

ironman, just to clarify, CF is on record saying Themis sold for between $100m and $500m, and he believes it was nearer the top end. Plus he has said he believes Imutex to be of similar value to Themis.

My view is Imutex would now have a value in excess of £500m.

Thanks ten-bagger for your views. Can't see why the bulletin board police aren't interested in considering all the options.

The Merck pharma acquisition of the Vienna-based vaccine company Themis should encourage some of Merck’s competitors to look more closely at Imutex and what we have to offer. We all know there’s a huge and growing interest in big pharma in the vaccine services and product development space and when one of the big pharma makes a move such as Merck did generally the other big pharma players follow suit by doing a copycat acquisition.
My own view is that Imutex, which we have a 49% stake in, the 100% immune modulator stake, and the 62.6% PrEPBiopharm stake the intention will be to vend 100% of all of these into an existing Nasdaq and London listed SPAC. This could provide a bigger return than selling to a big pharma.

Ten-bagger, I think they will be looking for a London and NASDAQ listed SPAC to vend Imutex into.

I take it this means they are swiftly moving on to phase 2.

https://www.aljazeera.com/amp/news/2020/06/vaccine-hunt-mosquito-saliva-stop-viruses-200613155937992.html